Diagnosis and Management of Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma: A Case Report and Review of the Literature

Shen, Angeline; King, James; Colman, Peter; Yates, Christopher J

doi:10.2217/frd-2021-0007

Cited by 1 publication

(1 citation statement)

References 80 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Temozolomide (TMZ), an alkylating chemotherapy agent, has shown efficacy in the treatment of PC,[ 20 ] but sustained treatment responses are uncommon, with frequent disease progression and a 2-year survival rate not exceeding 50%. [ 21 – 23 ]…”

Section: Introductionmentioning

confidence: 99%

Recent Therapeutic Advances in Pituitary Carcinoma

Robertson

Gregory

Waguespack

et al. 2022

Journal of Immunotherapy and Precision Oncology

View full text Add to dashboard Cite

Pituitary carcinoma (PC) is a rare, aggressive malignancy that comprises 0.1–0.2% of all pituitary tumors. PC is defined anatomically as a pituitary tumor that metastasizes outside the primary intrasellar location as noncontiguous lesions in the central nervous system or as metastases to other organs. Similar to pituitary adenoma, PC originates from various cell types of the pituitary gland and can be functioning or nonfunctioning, with the former constituting the majority of the cases. Compression of intricate skull-based structures, excessive hormonal secretion, impaired pituitary function from therapy, and systemic metastases lead to debilitating symptoms and a poor survival outcome in most cases. PC frequently recurs despite multimodality treatments, including surgical resection, radiotherapy, and biochemical and cytotoxic treatments. There is an unmet need to better understand the pathogenesis and molecular characterization of PC to improve therapeutic strategies. As our understanding of the role of signaling pathways in the tumorigenesis of and malignant transformation of PC evolves, efforts have focused on targeted therapy. In addition, recent advances in the use of immune checkpoint inhibitors to treat various solid cancers have led to an interest in exploring the role of immunotherapy for the treatment of aggressive refractory pituitary tumors. Here, we review our current understanding of the pathogenesis, molecular characterization, and treatment of PC. Particular attention is given to emerging treatment options, including targeted therapy, immunotherapy, and peptide receptor radionuclide therapy.

show abstract

Section: Introductionmentioning

confidence: 99%